February 23, 2021
Following significant growth in the past year and in anticipation of additional growth in the future, the Company has elected to add additional resources to its financial department. Brian Brown’s previous experience includes CFO, Vice President of Accounting & Investor Relations, and Director of Finance roles for public and private companies.
Brian Brown said, “By virtually every measure, Co-Diagnostics is a true success story. I was immediately drawn to the Company’s vision and ability to run a profitable, well-managed operation during a period of dynamic growth. I look forward to bringing my experience to support the Company in these endeavors.”
Dr. Jesse Montgomery, Ph.D. has also been elevated to the role of Chief Scientific Officer (“CSO”). “Our Company vision, technology platform, and experience are some of our greatest assets, which combined with the groundwork laid by Dr. Satterfield’s vision have all primed the Company for success,” remarked Dr. Montgomery. “I am excited to oversee the Company’s current and future scientific endeavors as Co-Diagnostics continues to progress and innovate in the field of molecular diagnostics.” Dr. Montgomery has been the Company’s Senior Vice President of Biochemistry, following a career that has included research and bioinformatics scientist positions.
Reed Benson, former CFO, will remain with the Company as general counsel, and Dr. Brent Satterfield, founder and former CSO, will continue his involvement with Co-Diagnostics as Head of the Scientific Advisory Board.
Dr. Satterfield commented: “It has been my pleasure to serve as CSO for Co-Diagnostics. In my new capacity as Head of the Scientific Advisory Board, I look forward to exploring new, innovative ways to further strengthen our scientific base, and advancing our ongoing goal of meeting global health challenges by providing affordable, state-of-the-art diagnostic solutions to the world community.”